Lenna Science<4889.T>finished the morning session of trading with a stop high of 80 yen at 382 yen. On the morning of the 9th at 8:30, the company announced results from a Phase 1 clinical trial for "RS5441" (topical and oral medication), which grants exclusive implementation rights to the USA's Eirion Therapeutics, and the results of the trial for the topical medication "ET-02" with RS5441 as the main ingredient were seen as notable for male pattern baldness and age-related hair loss.
The Phase 1 clinical trial was conducted as a double-blind placebo-controlled study consisting of either a placebo or a 1.25% or 5% solution of ET...
Login or create a forever free account to read this news
Sign up/Log in
